Immunohistochemistry (IHC) and flow cytometry are highly respected technologies
for the diagnosis of cancer and infectious disease. They are widely used
by pathologists and increasingly used by large pharmaceutical and biotechnology
companies to assist in target validation and the discovery of new drugs.

The growth of the market will be driven by the opportunity to take advantage
of the valuable information emerging from the post-genome era. The ability
to investigate and apply new markers that are characteristic of specific
genotypes and phenotypes in molecular tissue pathology will provide additional
information regarding diagnosis, prognosis, and response to various treatment
regimens.

RCAT is the first amplification method that is truly compatible with today’s
cellular analysis requirements. RCAT is also the first amplification method
to deliver increased sensitivity and multiplexing capability in both IHC
and flow cytometry applications without destroying precious morphological
context. This enables clinicians and researchers to access additional
information for diagnosis, prognosis, and response to therapy.

Advantages of RCAT for Cells and Tissues:

• Offers a significant increase in sensitivity with no loss in specificity, allowing detection of rare cells or foci of abnormal cells
• Enables identification of target antigens in their exact cellular geography
• Enables detection and analysis of several markers simultaneously
• Improves relative discrimination between cell populations
• Permits quantitative analysis of dispersed cell samples in flow cytometry
• Ideally suits cell- and tissue-based assays through its isothermal nature and its ability to maintain morphological information
• Eliminates need for destructive epitope retrieval methods